Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
Authors Esteban Jódar-Gimeno
Published Date May 2007 Volume 2007:2(1) Pages 163—174
Published 16 May 2007
Endocrinology and Metabolism Service, University Hospital “12 de Octubre”, Madrid, Spain. Associate Professor of Medicine Universidad Complutense, Madrid, Spain
Objective: To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis.
Sources: A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory agencies.
Study and data selection: Studies were selected according to relevance and availability. Relevant information (design, objectives, patients’ characteristics, outcomes, adverse events, dosing, etc) was analyzed.
Results: Different studies have shown that, when administered intermittently as a subcutaneous injection in the abdomen, PTH increases bone mineral density (BMD) and prevents vertebral fractures. On completion of PTH therapy (up to 24 months), there is evidence that sequential treatment with alendronate is associated with a therapeutic benefit in terms of increase in BMD. Further trials are necessary to determine long-term safety and the role of PTH in combination with other treatments for osteoporosis and the effect of repeated cycles of PTH followed by an anti-catabolic agent. There are currently no completed comparative trials with other osteoporosis treatments.
Conclusions: Full length PTH, given intermittently as an abdominal subcutaneous injection, appears to be a safe and efficacious treatment option for high risk osteoporosis. More data are needed to determine its specific role in osteoporosis treatment.
Keywords: postmenopausal osteoporosis, anabolic therapy, PTH (1–84)
Readers of this article also read:
Personalized therapeutics of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
Zhu LL, Feng ZJ, Zhou Q
Published Date: 26 March 2015
Effect of 6 months of whole body vibration on lumbar spine bone density in postmenopausal women: a randomized controlled trial [Corrigendum]
Lai CL, Tseng SY, Chen CN, Liao WC, Wang CH, Lee MC, Hsu PS
Published Date: 18 June 2014
Published Date: 16 May 2014
Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm [Corrigendum]
Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L
Published Date: 13 June 2013
Radiofrequency-targeted vertebral augmentation versus traditional balloon kyphoplasty: radiographic and morphologic outcomes of an ex vivo biomechanical pilot study [Erratum]
Published Date: 5 June 2013
Qu X, Yao C, Wang J, Li Z, Zhang Z
Published Date: 26 April 2013
The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia
Shao IH, Hou CP, Chen SM, Chen CL, Lin YH, Chang PL, Tsui KH
Published Date: 16 April 2013
Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica [Erratum]
Wang Z, Chen B, Quan G, Li F, Wu Q, Dian L, Dong Y, Li G, Wu C
Published Date: 7 February 2013
Published Date: 18 September 2012